Skip to main content
. 2006 Sep 28;65(12):1572–1577. doi: 10.1136/ard.2006.056747

graphic file with name ar56747.f1.jpg

Figure 1 Patients (%) achieving an Assessment in Ankylosing Spondylitis 20 response at week 12 in the etanercept‐treatment groups and the demonstration of non‐inferiority of etanercept 50 mg once weekly (QW) to etanercept 25 mg twice weekly (BIW; modified intent‐to‐treat population; last‐observation‐carried‐forward approach).